Global Ulcerative Colitis Drug Market Size Hit USD 12.20 Billion at a CAGR of 5.1% in 2030

The global ulcerative colitis drug market size was USD 7.80 Billion in 2021 and is expected to register a revenue CAGR of 5.1% over the forecast period, according to the latest report by Reports and Data.

Some of the important drivers driving the global ulcerative colitis drug market revenue growth include the growing incidence of ulcerative colitis and other Inflammatory Bowel Diseases (IBD), the development of biosimilars, and the rising demand for IBD treatment in emerging nations. The focus on diagnosis and therapy to minimise and manage signs and symptoms of ulcerative colitis is increasing demand for ulcerative colitis medications. There is currently no permanent cure for ulcerative colitis, and the exact cause of its occurrence is unknown, but there are several types of drugs that are effective in treating the symptoms. The type of medication or remedy prescribed to a patient is heavily influenced by the cause and severity of the disease.

The global ulcerative colitis medicine market is being fueled by a rise in the prevalence of ulcerative colitis and inflammatory bowel disease (IBD) throughout the world. Crohn’s disease and ulcerative colitis are the most common inflammatory gastrointestinal illnesses in IBD. Significant frequency and incidence rates of these disorders have been seen in rich nations. Furthermore, the market is growing as a result of drug approval. For example, in November 2021, the European Commission granted Bristol Myers Squibb approval to market Zeposia (ozanimod) for the treatment of adults with moderate to severe active Ulcerative Colitis (UC) who have received insufficient, lost response, or are intolerable to either conventional therapy or a biologic agent.

Companies profiled in the market report include Johnson & Johnson Services, Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Bristol-Myers Squibb Company, EA Pharma Co., Ltd., Elli Lilly and Company, Novartis AG, Merck & Co., Inc., Reistone Biophrma, and Bausch Health Companies Inc.

Get a sample of the report @ https://www.reportsanddata.com/download-free-sample/2379

Market Overview:

The research report assesses the market dynamics, market landscape, company profiles, production and manufacturing capacity, year-on-year growth rate, SWOT analysis, and Porter’s Five Forces analysis. The report estimates the market size, market growth, and provides an accurate forecast for the key segments of the market for the forecast period of 2022-2030. The report also covers an in-depth analysis of the key competitors of the market, along with their growth strategies and business expansion plans.

The Ulcerative Colitis Drug Market has been segmented into key regions of the world and offers an analysis of growth rate, market share, market size, current and emerging trends, production and consumption ratio, industrial chain analysis, demand and supply, import and export, revenue contribution, and presence of key players in each region. A country-wise analysis of the market is offered in the report to gain a better understanding of the regional spread and progress of the Ulcerative Colitis Drug Market.

Further key findings from the report suggest,

• The global ulcerative colitis drug market is divided into biologics, corticosteroids, immunomodulators, 5-aminosalicylic acid, immunosuppressants, biosimilars, and others based on medication type. The biologics section accounted for the biggest revenue share in 2021 because to its ability to function selectively rather than affecting the entire body, resulting in fewer medication-related adverse effects and increased preference among care providers and care users.
• During the projected period, the immunomodulators segment is predicted to have the highest revenue growth rate. This class of medications limits or modulates the body’s immune response, preventing it from continuing inflammation. Immunomodulators are often used when corticosteroids and aminosalicylates have failed to function or have only partially worked, which might take months to become effective.
• According to geographical analysis, the North America market is predicted to have the highest revenue share throughout the forecast period because to the sophisticated healthcare system in the United States, an increase in illness information and awareness among people, and technological innovation in this area. Furthermore, the high prevalence and growing incidence of Crohn’s disease and ulcerative colitis in the United States and Canada, as well as the area’s established healthcare system and high risk of lifestyle-related variables, are driving revenue growth in this region. Furthermore, the global IBD (ulcerative colitis and Crohn’s disease) therapeutic market in this area is projected to be driven by top competitors’ strong product pipelines. The market’s development is also supported by the market’s members’ increased research activities.
• AbbVie announced in June 2022 that the US Food and Drug Administration (FDA) has authorised SKYRIZI as the first and only specific Interleukin-23 (IL-23) to treat moderately to highly active Crohn’s disease in adults.

To understand how our Ulcerative Colitis Drug Market can bring difference to your business strategy:– https://www.reportsanddata.com/report-detail/ulcerative-colitis-drug-market

For the purpose of this report, Reports and Data has segmented the global ulcerative colitis drug industry into drug type, route of administration, distribution channel, application, and region:

Drug Type Outlook (Revenue, USD Billion; 2019-2030)

• Biologics
• Corticosteroids
• Immunomodulators
• 5-aminosalicylic Acid
• Immunosuppressant
• Biosimilars
• Others

Route of Administration Outlook (Revenue, USD Billion; 2019-2030)

• Oral
• Injectable

Distribution Channel Outlook (Revenue, USD Billion; 2019-2030)

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Application Outlook (Revenue, USD Billion; 2019-2030)

• Proctosigmoiditis
• Ulcerative Proctitis
• Pancolitis
• Left-sided Colitis
• Acute Severe Ulcerative Colitis

Regional Outlook (Revenue, USD Billion; 2019-2030)

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Sweden
  • BENELUX
  • Rest of Europe
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Rest of LATAM
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Israel
  • Rest of MEA

Request a customization of the report : https://www.reportsanddata.com/request-customization-form/2379

 Key Advantages of Ulcerative Colitis Drug Market Report:

• Identification and analysis of the market size and competition
• Qualitative and quantitative analysis of the market data
• Data validated by industry experts after extensive primary and secondary research
• Extensive regional analysis of the Ulcerative Colitis Drug industry
• Profiling of key players along with their business overview, business strategies, deals and partnerships, and product portfolio
• SWOT and Porter’s Five Forces Analysis for in-depth understanding of the competitive landscape
• Feasibility analysis and investment analysis to enable strategic investment decisions
• Analysis of opportunities, drivers, restraints, challenges, risks, and limitations

Conclusively, all aspects of the Ulcerative Colitis Drug Market are quantitatively as well qualitatively assessed to study the global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects.

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Contact Us:

John W
Head of Business Development
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Reports and Data | Web: www.reportsanddata.com
Check our upcoming research reports @ https://www.reportsanddata.com/upcoming-reports
Visit our blog for more industry updates @ https://www.reportsanddata.com/blogs

Image Credit

Browse More Reports:

https://www.biospace.com/article/thoracic-stent-graft-market-analysis-by-current-industry-status-and-growth-opportunities-top-key-players-target-audience-and-forecast-to-2028-/

https://www.biospace.com/article/temporary-pacemaker-market-size-share-trends-growth-industry-analysis-company-profiles-and-forecast-by-2028/

https://www.biospace.com/article/syphilis-rapid-test-kit-market-size-share-industry-key-features-growth-drivers-key-expansion-strategies-upcoming-trends-and-regional-forecast-by-2028/

https://www.biospace.com/article/pet-ct-scan-market-size-share-top-key-players-growth-trend-and-forecast-till-2028/

The post Global Ulcerative Colitis Drug Market Size Hit USD 12.20 Billion at a CAGR of 5.1% in 2030 appeared first on Market O Graphics.